Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;102(1):67-70.
doi: 10.1308/rcsann.2019.0111. Epub 2019 Sep 11.

Congenital mesoblastic nephroma: a single-centre series

M Pachl  1 , G S Arul  1 , I Jester  1 , C Bowen  2 , D Hobin  3 , B Morland  3
Affiliations

Congenital mesoblastic nephroma: a single-centre series

M Pachl et al. Ann R Coll Surg Engl. 2020 Jan.

Abstract

Background: Congenital mesoblastic nephroma is a rare disease. Treatment is surgical in the first instance. Chemotherapy has traditionally been thought not to have a role. Recent literature suggests a 50% mortality rate for recurrent/metastatic disease.

Materials and methods: This study is a retrospective case review of prospectively collected data. Demographics, histopathology, treatment, outcomes and follow up were reviewed.

Results: Nine patients, 6 male and 3 female, were included. The median age at presentation was one month (range 0-7 months); follow-up was for a median of 21.5 months (range 16-79 months). Two patients had mixed and classical subtypes and the other five had the cellular subtype. Surgery was completed by an open procedure in eight patients and laparoscopically in one. There were three recurrences; two were local and one was pulmonary. Recurrences were treated with a combination of chemotherapy, radiotherapy and surgery. One patient with recurrent disease died from acute-on-chronic respiratory failure secondary to lung irradiation but was disease free. The other eight are disease free, alive and well with no sequelae at latest follow-up.

Conclusions: Surgery remains the mainstay of management with chemo- and radiotherapy reserved for unresectable tumours or adjuvant management of recurrent disease. Specimen-positive margins are not an indication for instituting chemotherapy. The tyrosine kinase pathway seems to be a potential target for future chemotherapeutic agents although it is too early to assess how that will impact on the management of congenital mesoblastic nephroma.

Keywords: Chemotherapy; Mesoblastic nephroma; Radiotherapy; Surgery.

PubMed Disclaimer

References

    1. Furtwaengler R, Reinhard H, Leuschner I et al. . Gesellschaft fur Pädiatrische Onkologie und Hämatologie (GPOH) Nephroblastoma Study Group. Mesoblastic nephroma: a report from the Gesellschaft fur Pädiatrische Onkologie und Hämatologie (GPOH). Cancer 2006; : 2,275–2,283. - PubMed
    1. Bolande RP, Borough AJ, Izant RJ Jr. Congenital mesoblastic nephroma of infancy: a report of eight cases and the relationship to Wilms’ tumor. Paediatrics 1967; : 272–278. - PubMed
    1. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: congenital (infantile) fibrosarcoma and mesoblastic nephroma. Cancer Genet Cytogenet 2002; : 1–13. - PubMed
    1. Jehangir S, Kurian JJ, Selvarajah D et al. . Recurrent and metastatic congenital mesoblastic nephroma: where does the evidence stand? Pediatr Surg Int 2017; : 1,183–1,188. - PubMed
    1. Sandstedt B, Delemarre J, Krul EJ et al. . Mesoblastic nephromas: a study of 29 tumours from the SIOP nephroblastoma file. Histopathology 1985; : 741–750. - PubMed

MeSH terms